ONGAR, England & LUND, Sweden--(BUSINESS WIRE)--UK-based contract research organisation Selcia Limited and Swedish drug development company NeuroVive Pharmaceutical AB have signed a significant research collaboration agreement to develop new medicines and drug compounds targeting mitochondrial physiology and pathophysiology. The collaboration is focused on mitochondrial medicine, an emerging therapeutic modality that promises innovative new treatments for major chronic diseases, such as cancer and obesity, and acute conditions such as stroke and heart failure. Selcia and NeuroVive will jointly invest in the collaboration to combine Selcia´s leading expertise in medicinal and analytical chemistry, with NeuroVive´s advanced research and development programs in mitochondrial medicine.
Mitochondria are well known as the energy-producing powerhouses of all cells and are critical for optimal cellular function and survival, as well as initiating cell death. Research has implicated mitochondrial dysfunction in acute conditions: such as stroke and heart failure; chronic diseases like diabetes; within neurodegeneration, such as Alzheimer´s disease; and in the ageing process. Impaired cellular energy levels is a primary result of mitochondrial dysfunction, which has a number of causes ranging from free radical damage to genetic mutations. Mitochondrial medicines seek to optimise cellular energy levels and health through protecting or enhancing mitochondrial function.
Simon Saxby, CEO of Selcia, commented on the collaboration; “We are delighted to be collaborating with NeuroVive in the area of mitochondrial medicine. Our combined resources have the potential to yield a number of new drugs and supplements that could revolutionise the treatment of diseases caused by mitochondrial dysfunction, as well as recovery regimens for a number of patient populations”.
Mikael Brönnegård, CEO of NeuroVive Pharmaceutical, said, “In this collaboration with Selcia, NeuroVive will target the development of new drugs that are at the cutting edge for diseases like stroke, heart attack, obesity, and cancer – all large potential markets with significant burden of disease. This will add new drug entities to NeuroVive's broad development pipeline and will enable the company to capitalise on the commercial opportunities deriving from our leading expertise in mitochondrial research, including our cyclophilin-D program”.
NeuroVive´s CSO Eskil Elmér, added: “Mitochondrial medicine deals with conditions that are related to mitochondrial dysfunction (i.e., reduced or limited energy production) due to a number of causes ranging from specific genetic mutations to disease-related secondary mitochondrial damage. It also applies to situations requiring an increased energy demand, such as recovering from extensive surgery and intensive care and situations in which augmented energy expenditure (e.g., obesity) is important. This collaboration with Selcia will allow us to accelerate the discovery and development of new mitochondrial medicines and drug-like compounds within the scope of our current R&D budget in the discovery phase”.
ENDS
NOTES TO EDITOR
About Selcia
Selcia Limited (www.selcia.com) is a leading worldwide provider of contract research services in integrated drug discovery, fragment screening, medicinal chemistry and GMP certified 14-C custom radiolabelling services. Selcia operates from 2,800 sqm modern facilities with a GLP analytical laboratory, in Ongar, Essex, United Kingdom and Hopkinton, MA, USA.
Selcia’s Discovery division provides integrated drug discovery services to the pharmaceutical and biotechnology industries; these services include medicinal, organic and analytical chemistry, molecular modelling, in vitro biological screening, fragment screening, in vitro ADME/PK evaluation and in vivo PK (with a strategic partner). Selcia’s Radiolabelling division is a proven leader in delivering pure radiolabelled compounds for preclinical and clinical ADME studies.
About NeuroVive Pharmaceutical
NeuroVive Pharmaceutical AB (www.neurovive.com) is a Swedish drug development company whose primary mission is to develop drugs for the treatment of acute brain injury, reperfusion injury in myocardial infarction and other acute injuries where mitochondrial energy production is critical for clinical outcome. The research and development program focuses on developing new variants of cyclophilin-D-inhibiting cyclosporins and studying ways of transporting these drugs across the blood-brain barrier to the central nervous system.
NeuroVive´s shares are listed on the Swedish trading platform AktieTorget (www.aktietorget.se). The AktieTorget market is focused on emerging, entrepreneurial businesses through an electronic trading system supplied by the OMX Nordic stock exchange in Stockholm, Sweden.